Mitsubishi UFJ Asset Management Co. Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. $REGN

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 216,169 shares of the biopharmaceutical company’s stock after buying an additional 7,106 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $121,545,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of REGN. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at $31,000. Traub Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $38,000. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares in the last quarter. Finally, Berbice Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock valued at $4,142,738 over the last three months. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $770.79 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The company has a market cap of $81.49 billion, a P/E ratio of 18.55, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The firm’s 50-day moving average price is $771.32 and its 200-day moving average price is $679.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the business earned $12.07 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Scotiabank boosted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday, November 24th. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Finally, Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.